0001564590-21-055283.txt : 20211108 0001564590-21-055283.hdr.sgml : 20211108 20211108163620 ACCESSION NUMBER: 0001564590-21-055283 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oak Street Health, Inc. CENTRAL INDEX KEY: 0001564406 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 843446686 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39427 FILM NUMBER: 211388517 BUSINESS ADDRESS: STREET 1: 30 W. MONROE ST., STE. 1200 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: 312-773-3374 MAIL ADDRESS: STREET 1: 30 W. MONROE ST., STE. 1200 CITY: CHICAGO STATE: IL ZIP: 60603 FORMER COMPANY: FORMER CONFORMED NAME: Oak Street Health, LLC DATE OF NAME CHANGE: 20121211 8-K 1 osh-8k_20211108.htm 8-K osh-8k_20211108.htm
false 0001564406 0001564406 2021-11-08 2021-11-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2021

Oak Street Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-39427

 

84-3446686

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

 

30 W. Monroe Street

Suite 1200

Chicago, Illinois 60603

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (312) 733-9730

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

OSH

 

New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 


 

 

Item 2.02. Results of Operations and Financial Condition.

On November 8, 2021, Oak Street Health, Inc. issued a press release announcing its financial results for its third quarter ended September 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information contained in this Current Report on Form 8-K and in the accompanying exhibit are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

 

Description

99.1

 

Press Release Dated November 8, 2021

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2


 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 8, 2021

 

Oak Street Health, Inc.

 

 

 

By:

 

/s/ Tim Cook

Name:

 

Tim Cook

Title:

 

Chief Financial Officer

 

3

EX-99.1 2 osh-ex991_6.htm EX-99.1 osh-ex991_6.htm

Exhibit 99.1

Oak Street Health Reports Third Quarter 2021 results

November 8, 2021 at 4:05 Eastern Time

CHICAGO, IL – Oak Street Health, Inc. (NYSE: OSH, or the “Company”), a network of value-based primary care centers for adults on Medicare, today reported financial results for its quarter ended September 30, 2021.

 

“We were pleased with another quarter of strong performance as well as the significant accomplishments we made to advance our platform,” said Mike Pykosz, Chief Executive Officer of Oak Street Health. “We managed through the continued uncertainty related to the COVID-19 pandemic and Delta variant, eclipsing $1 billion of revenue for the first time in our Company’s history.  We are encouraged by our clinical results in the third quarter and their implications for both our patients’ well-being and our future financial performance.  We were also proud to announce two important milestones – our relationship with AARP and our acquisition of RubiconMD.  Oak Street Health became the only primary care group selected to carry the AARP name, which is truly meaningful recognition from one of the most respected brands among seniors.  With our acquisition of RubiconMD, we are excited by the opportunity to integrate specialist expertise directly into the care we provide in-center which further differentiates and improves the Oak Street Platform.  We believe these advancements will accelerate our mission to rebuild healthcare as it should be into 2022 and beyond.”

 

“In the third quarter, we generated at-risk patient growth of 69%, and total revenue growth of 78%, and continued our national expansion, opening 15 new centers in 7 new markets, bringing our total center count to 100,” added Tim Cook, Chief Financial Officer of Oak Street Health. “Additionally, we outperformed on our key metrics of at-risk patients, total revenue, and adjusted EBITDA compared to our guidance for the quarter and are excited by our momentum heading into 2022.”

 

Third Quarter 2021 Financial Highlights

 

Total revenue was $388.7 million, up 78% year over year.

 

Capitated revenue totaled $376.7 million, up 78% year over year.

 

The Company cared for approximately 100,500 risk-based patients, representing 76% of its total patients.

 

Net loss was $(109.9) million 1, compared to $(59.3) million in the third quarter of 2020.

 

Adjusted EBITDA2 was $(64.3) million, compared to $(22.8) million in the third quarter of 2020.

 

As of September 30, 2021, the Company operated 110 centers, compared to 67 centers as of September 30, 2020.

Outlook for Fiscal Year 2021

 

 

 

Twelve Months Ending

 

 

 

December 31, 2021

 

 

 

Low

 

 

High

 

(dollars in millions)

 

 

Centers

 

 

128

 

 

 

129

 

At-risk patients

 

 

111,500

 

 

 

113,500

 

Revenue

$

 

1,400.0

 

 

 

1,425.0

 

Adjusted EBITDA

$

 

(230.0

)

 

 

(235.0

)

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not

 

1 

Includes stock based and unit-based compensation of $38.7 million and $29.7 million as of the third quarter of 2021 and 2020, respectively. The majority of the increase is due to the modification of vesting terms for pre-IPO equity awards that occurred post-IPO (2020 included approximately one and a half months of expense due to the timing of our IPO) and not incremental grants of equity.

 

2 

Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure and is reconciled to net loss as the most directly comparable GAAP measure as set forth in the accompanying “Adjusted EBITDA Reconciliation” section. We define Adjusted EBITDA as net loss, excluding other income (expense), taxes, depreciation and amortization, stock-based and unit-based compensation and transaction/ offering related costs.

1


provided forward-looking guidance for net loss, because of the uncertainty around certain items that may impact net loss, including stock-based and unit-based compensation, that are not within our control or cannot be reasonably predicted. However, for fiscal year 2021, depreciation and amortization is expected to be $16.0 million.

Webcast and Conference Call

The Company will conduct a conference call Tuesday, November 9, 2021 at 8:00 AM Eastern Time to discuss these results and management’s outlook for future financial and operational performance. The conference call can be accessed by webcast or by dialing (833) 529-0224 for U.S. participants, or +1 (236) 389-2153 for international participants, and referencing participant code 5142299. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at https://investors.oakstreethealth.com.

About Oak Street Health

Founded in 2012, Oak Street Health is a network of value-based primary care centers for adults on Medicare. With a mission of rebuilding healthcare as it should be, the Company operates an innovative healthcare model focused on quality of care over volume of services, and assumes the full financial risk of its patients. Oak Street Health currently operates more than 100 centers across 19 states and is the only primary care provider to carry the AARP name. To learn more about Oak Street Health’s proven approach to care, visit oakstreethealth.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the fiscal year 2021. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the final Registration Statement filed with the SEC on August 5, 2020, and the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 10, 2021. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

2


Condensed Consolidated Balance Sheets

(in millions)

 

 

September 30, 2021 (unaudited)

 

 

December 31, 2020

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash

$

 

241.7

 

$

 

409.3

 

Restricted cash

 

 

16.6

 

 

 

10.4

 

Other patient receivables, net

 

 

0.5

 

 

 

7.6

 

Capitated accounts receivable

 

 

464.0

 

 

 

248.9

 

Marketable debt securities

 

 

771.3

 

 

 

-

 

Prepaid expenses

 

 

9.6

 

 

 

6.8

 

Other current assets

 

 

11.1

 

 

 

4.2

 

Total current assets

 

 

1,514.8

 

 

 

687.2

 

 

 

 

 

 

 

 

 

 

Long-term assets:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

112.7

 

 

 

78.8

 

Security deposits

 

 

1.6

 

 

 

1.3

 

Operating lease right-of-use assets

 

 

145.9

 

 

 

-

 

Goodwill

 

 

12.5

 

 

 

9.6

 

Intangible assets, net

 

 

2.7

 

 

 

3.0

 

Other long-term assets

 

 

0.8

 

 

 

1.1

 

Total assets

$

 

1,791.0

 

$

 

781.0

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

$

 

30.2

 

$

 

8.8

 

Accrued compensation and benefits

 

 

38.4

 

 

 

32.0

 

Liability for unpaid claims

 

 

442.3

 

 

 

262.1

 

Other liabilities

 

 

34.0

 

 

 

12.6

 

Total current liabilities

 

 

544.9

 

 

 

315.5

 

 

 

 

 

 

 

 

 

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Long-term operating lease liabilities

 

 

153.0

 

 

 

-

 

Deferred rent expense

 

 

-

 

 

 

13.5

 

Other long-term liabilities

 

 

39.7

 

 

 

28.8

 

Long-term debt, net of current portion

 

 

900.3

 

 

 

-

 

Total liabilities

 

 

1,637.9

 

 

 

357.8

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

0.2

 

 

 

0.2

 

Additional paid-in capital

 

 

977.6

 

 

 

971.8

 

Accumulated other comprehensive income

 

 

(0.2

)

 

 

-

 

Accumulated deficit

 

 

(826.6

)

 

 

(555.8

)

Total stockholders' equity allocated to the Company

 

 

151.0

 

 

 

416.2

 

Noncontrolling interests

 

 

2.1

 

 

 

7.0

 

Total stockholders' equity

 

 

153.1

 

 

 

423.2

 

Total liabilities, redeemable investor units and stockholders' equity

$

 

1,791.0

 

$

 

781.0

 

 

3


 

Condensed Consolidated Statements of Operations

(in millions, except per share data)

 

 

Three-Months Ended

 

 

Nine-Months Ended

 

 

 

September 30, 2021

 

 

September 30, 2020

 

 

September 30, 2021

 

 

September 30, 2020

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capitated revenue

$

 

376.7

 

$

 

211.8

 

$

 

1,014.6

 

$

 

616.4

 

Other patient service revenue

 

 

12.0

 

 

 

6.1

 

 

 

23.9

 

 

 

17.7

 

Total revenues

 

 

388.7

 

 

 

217.9

 

 

 

1,038.5

 

 

 

634.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical claims expense

 

 

309.7

 

 

 

154.5

 

 

 

790.9

 

 

 

442.3

 

Cost of care, excluding depreciation and amortization

 

 

76.3

 

 

 

43.2

 

 

 

203.6

 

 

 

126.5

 

Sales and marketing

 

 

30.5

 

 

 

15.5

 

 

 

80.5

 

 

 

37.4

 

Corporate, general and administrative expenses

 

 

77.0

 

 

 

57.2

 

 

 

224.3

 

 

 

112.5

 

Depreciation and amortization

 

 

4.5

 

 

 

2.9

 

 

 

11.7

 

 

 

8.1

 

Total operating expenses

 

 

498.0

 

 

 

273.3

 

 

 

1,311.0

 

 

 

726.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(109.3

)

 

 

(55.4

)

 

 

(272.5

)

 

 

(92.7

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income/(expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(0.6

)

 

 

(3.9

)

 

 

(1.8

)

 

 

(8.8

)

Other

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.2

 

Total other expense

 

 

(0.6

)

 

 

(3.9

)

 

 

(1.8

)

 

 

(8.6

)

Net loss

$

 

(109.9

)

$

 

(59.3

)

$

 

(274.3

)

$

 

(101.3

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to noncontrolling interests

 

 

0.6

 

 

 

0.1

 

 

 

3.5

 

 

 

0.5

 

Net loss attributable to the Company

$

 

(109.3

)

$

 

(59.2

)

$

 

(270.8

)

$

 

(100.8

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Undeclared and deemed dividends

$

 

-

 

$

 

(5.4

)

$

 

-

 

$

 

(27.2

)

Net loss attributable to common stock/unitholders

 

 

(109.3

)

 

 

(64.6

)

 

 

(270.8

)

 

 

(128.0

)

Weighted average common stock outstanding - basic and diluted3

 

 

223,435,698

 

 

 

218,261,866

 

 

 

221,932,624

 

 

 

218,261,866

 

Net loss per share – basic and diluted

$

 

(0.49

)

 

 

(0.15

)

$

 

(1.22

)

 

 

(0.15

)

 

3 

Basic and diluted earnings per share of common stock is applicable only for periods after the Company's IPO that was completed on August 10, 2020.

4


 

Condensed Consolidated Statements of Cash Flows

(in millions, unaudited)

 

 

Nine-Months Ended

 

 

 

September 30, 2021

 

 

September 30, 2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

$

 

(274.3

)

$

 

(101.3

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Amortization of discount on debt and related issuance costs

 

 

2.4

 

 

 

4.2

 

Accretion of discounts and amortization of premiums on short-term marketable securities, net

 

 

2.4

 

 

 

-

 

Depreciation and amortization

 

 

11.7

 

 

 

8.1

 

Non-cash operating lease costs

 

 

11.2

 

 

 

-

 

Stock and unit-based compensation, net of forfeitures

 

 

121.9

 

 

 

34.4

 

Change in fair value of bifurcated derivative

 

 

-

 

 

 

0.2

 

Change in operating assets and liabilities, net of impact of acquisitions:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(208.0

)

 

 

(56.3

)

Prepaid expenses and other current assets

 

 

(10.6

)

 

 

(6.1

)

Security deposits and other long-term assets

 

 

0.1

 

 

 

0.1

 

Accounts payable

 

 

16.6

 

 

 

(5.9

)

Accrued compensation and benefits

 

 

6.5

 

 

 

(5.2

)

Liability for unpaid claims

 

 

180.2

 

 

 

86.6

 

Operating lease liabilities

 

 

(9.9

)

 

 

-

 

Other current liabilities

 

 

7.9

 

 

 

10.7

 

Other long-term liabilities

 

 

16.0

 

 

 

7.8

 

Other

 

 

-

 

 

 

0.4

 

Net cash used in operating activities

 

 

(125.9

)

 

 

(22.3

)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Proceeds from sales and maturities of marketable debt securities

 

 

43.7

 

 

 

-

 

Purchases of marketable debt securities

 

 

(817.6

)

 

 

-

 

Purchase of business

 

 

(1.4

)

 

 

-

 

Purchases of property and equipment

 

 

(40.6

)

 

 

(12.6

)

Net cash used in investing activities

 

 

(815.9

)

 

 

(12.6

)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from initial public offering

 

 

-

 

 

 

377.3

 

Payments of underwriting fees, net of discounts and offering costs

 

 

-

 

 

 

(24.9

)

Principal payments on long-term debt

 

 

-

 

 

 

(80.0

)

End of term charge and prepayments for debt paydown

 

 

-

 

 

 

(5.6

)

Proceeds from borrowings on convertible senior notes, net

 

 

897.9

 

 

 

-

 

Purchase of capped calls

 

 

(123.6

)

 

 

-

 

Proceeds from issuance of redeemable investor units

 

 

-

 

 

 

224.4

 

Capital contributions from non-controlling interests

 

 

0.1

 

 

 

5.9

 

Capital distributions to non-controlling interests

 

 

(1.5

)

 

 

(0.1

)

Tender Offer - common units

 

 

-

 

 

 

(19.4

)

Proceeds from exercise of options

 

 

4.5

 

 

 

0.1

 

Proceeds from issuance of common stock under the employee purchase plan

 

 

3.0

 

 

 

-

 

Net cash provided by financing activities

 

 

780.4

 

 

 

477.7

 

 

 

 

 

 

 

 

 

 

Net change in cash, cash equivalents and restricted cash

 

 

(161.4

)

 

 

442.8

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

419.7

 

 

 

42.2

 

Cash, cash equivalents and restricted cash, end of period

$

 

258.3

 

$

 

485.0

 

 

5


 

Non-GAAP Financial Measures

Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following Non-GAAP measures: patient contribution, platform contribution and Adjusted EBITDA as these are performance measures that our management uses to assess our operating performance. Because patient contribution, platform contribution and Adjusted EBITDA facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Patient Contribution Reconciliation

Patient Contribution is a non-GAAP financial measure that we define as capitated revenue less medical claims expense. The following is a reconciliation of our loss from operations, the most directly comparable GAAP financial measure, to Patient Contribution, for the three and nine-months ended September 30, 2021 and 2020.

 

 

Three-Months Ended

 

 

Nine-Months Ended

 

(dollars in millions), (unaudited)

 

September 30, 2021

 

 

September 30, 2020

 

 

September 30, 2021

 

 

September 30, 2020

 

Loss from operations

$

 

(109.3

)

$

 

(55.4

)

$

 

(272.5

)

$

 

(92.7

)

Other patient service revenue

 

 

(12.0

)

 

 

(6.1

)

 

 

(23.9

)

 

 

(17.7

)

Cost of care, excluding depreciation and amortization

 

 

76.3

 

 

 

43.2

 

 

 

203.6

 

 

 

126.5

 

Sales and marketing

 

 

30.5

 

 

 

15.5

 

 

 

80.5

 

 

 

37.4

 

Corporate, general and administrative expenses

 

 

77.0

 

 

 

57.2

 

 

 

224.3

 

 

 

112.5

 

Depreciation and amortization

 

 

4.5

 

 

 

2.9

 

 

 

11.7

 

 

 

8.1

 

Patient contribution

$

 

67.0

 

$

 

57.3

 

$

 

223.7

 

$

 

174.1

 

Platform Contribution Reconciliation

Platform Contribution is a non-GAAP financial measure that we define as total revenues less the sum of medical claims expense and cost of care, excluding depreciation and amortization. The following is a reconciliation of our loss from operations, the most directly comparable GAAP financial measure, to Platform Contribution, for the three and nine-months ended September 30, 2021 and 2020.

 

 

Three-Months Ended

 

 

Nine-Months Ended

 

(dollars in millions), (unaudited)

 

September 30, 2021

 

 

September 30, 2020

 

 

September 30, 2021

 

 

September 30, 2020

 

Loss from operations

$

 

(109.3

)

$

 

(55.4

)

$

 

(272.5

)

$

 

(92.7

)

Depreciation and amortization

 

 

4.5

 

 

 

2.9

 

 

 

11.7

 

 

 

8.1

 

Corporate, general and administrative

 

 

77.0

 

 

 

57.2

 

 

 

224.3

 

 

 

112.5

 

Sales and marketing

 

 

30.5

 

 

 

15.5

 

 

 

80.5

 

 

 

37.4

 

Platform contribution

$

 

2.7

 

$

 

20.2

 

$

 

44.0

 

$

 

65.3

 

Adjusted EBITDA Reconciliation

Adjusted EBITDA is a non-GAAP financial measure that we calculate as net loss adjusted to exclude (i) stock and unit-based compensation expense, (ii) depreciation and amortization, (iii) other income, net and (iv) transaction and offering costs. Our management team uses Adjusted EBITDA as a performance measure in order to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three and nine-months ended September 30, 2021 and 2020.

 

6


 

 

 

Three-Months Ended

 

 

Nine-Months Ended

 

(dollars in millions), (unaudited)

 

September 30, 2021

 

 

September 30, 2020

 

 

September 30, 2021

 

 

September 30, 2020

 

Net loss

$

 

(109.9

)

$

 

(59.3

)

$

 

(274.3

)

$

 

(101.3

)

Interest expense and other income

 

 

0.6

 

 

 

3.9

 

 

 

1.8

 

 

 

8.6

 

Depreciation and amortization

 

 

4.5

 

 

 

2.9

 

 

 

11.7

 

 

 

8.1

 

Stock and unit-based compensation

 

 

38.7

 

 

 

29.7

 

 

 

121.9

 

 

 

35.6

 

Transaction / offering related costs

 

 

1.8

 

 

 

-

 

 

 

3.6

 

 

 

-

 

Adjusted EBITDA

$

 

(64.3

)

$

 

(22.8

)

$

 

(135.3

)

$

 

(49.0

)

Contacts

Media:

Erica Frank

Vice President of Public Relations

(330) 990-5026

Erica.Frank@oakstreethealth.com

Investors:

Sarah Cluck
Head of Investor Relations

(773) 572-0254
sarah.cluck@oakstreethealth.com

 

 

Source: Oak Street Health

 

7

EX-101.SCH 3 osh-20211108.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 osh-20211108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 osh-20211108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 osh-8k_20211108_htm.xml IDEA: XBRL DOCUMENT 0001564406 2021-11-08 2021-11-08 false 0001564406 8-K 2021-11-08 Oak Street Health, Inc. DE 001-39427 84-3446686 30 W. Monroe Street Suite 1200 Chicago IL 60603 (312) 733-9730 false false false false Common Stock, $0.001 par value OSH NYSE true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 08, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001564406
Document Type 8-K
Document Period End Date Nov. 08, 2021
Entity Registrant Name Oak Street Health, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39427
Entity Tax Identification Number 84-3446686
Entity Address, Address Line One 30 W. Monroe Street
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60603
City Area Code (312)
Local Phone Number 733-9730
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol OSH
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports osh-8k_20211108.htm osh-20211108.xsd osh-20211108_lab.xml osh-20211108_pre.xml osh-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "osh-8k_20211108.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "osh-8k_20211108.htm" ] }, "labelLink": { "local": [ "osh-20211108_lab.xml" ] }, "presentationLink": { "local": [ "osh-20211108_pre.xml" ] }, "schema": { "local": [ "osh-20211108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "osh", "nsuri": "http://www.oakstreethealth.com/20211108", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "osh-8k_20211108.htm", "contextRef": "C_0001564406_20211108_20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "osh-8k_20211108.htm", "contextRef": "C_0001564406_20211108_20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.oakstreethealth.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-21-055283-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-055283-xbrl.zip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end